Evogliptin
As of the edition of 20 October 2026, Evogliptin is a small molecule: marketed, first approved in 2015 (KR); acts on DPP4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- First approved
- 2 October 2015 (KR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Dong-A ST
- Registered trials
- 32, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Digestive system; Bones, joints and muscles; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Evogliptin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DPP4 | Dipeptidyl peptidase 4 | P27487 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 16 | 10 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 8 | 2 | 0 | 0 |
| All trials | 32 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Dong-A ST | Originator and Lead sponsor of trials | 2013 to now |